This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene

This study has been completed.
Information provided by (Responsible Party):
Janssen Research & Development, LLC Identifier:
First received: December 5, 2011
Last updated: March 1, 2013
Last verified: March 2013
The purpose of this study is to investigate the pharmacokinetics of OROS hydromorphone in healthy adult Taiwanese participants after the oral administration of a single 16 mg dose.

Condition Intervention Phase
Healthy Volunteers Drug: Hydromorphone 16 mg Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene

Resource links provided by NLM:

Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Plasma hydromorphone concentration [ Time Frame: 20 time points up to 72 hours post-dose ]

Secondary Outcome Measures:
  • Plasma hydromorphone 3-glucuronide concentration [ Time Frame: 20 time points up to 72 hours post-dose ]
  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Approximately 33 days ]

Enrollment: 29
Study Start Date: October 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hydromorphone 16 mg Drug: Hydromorphone 16 mg
type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.

Detailed Description:
This is a single-center, open-label (all people know the identity of the intervention), single-dose study in healthy adult Taiwanese participants. A minimum of 6 participants identified as having the UGT2B7 *2/*2 variant genotype and 12 participants identified as having the UGT2B7 *1/*1 wild type genotype will be included in the study. The study will explore the impact of genetic polymorphism in the UGT2B7 gene (occurrence of variants of this gene) on the pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) of OROS hydromorphone. This study consists of a screening phase followed by a 5-day open-label treatment phase. During the screening phase, a blood sample will be collected for a genetic test to confirm the presence of the UGT2B7 gene. During the study period, upon completion of a 12-hour overnight fast, participants will receive a single oral 16-mg dose of OROS hydromorphone in the morning of Day 1. Blood samples will be collected through 72 hours after dosing for the determination of plasma hydromorphone and hydromorphone 3-glucuronide concentrations. The safety and tolerability of 16-mg OROS hydromorphone will also be assessed. The total study duration for each participant is approximately 33 days.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Participation in the DNA analysis to confirm UGT2B7 genotype status
  • Body mass index (BMI) between 18 and 25 kg/m², inclusive and a body weight of not less than 50 kg
  • Participants must utilize a medically acceptable method of contraception throughout the entire study period and for 1 month after the study is completed
  • Each participant will receive a naloxone challenge test for opioid dependency at screening. Only those participants who pass this challenge test will be allowed to continue in the study

Exclusion Criteria:

  • History of or current clinically medical illness or any other condition that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Clinically significant abnormal values for hematology, clinical chemistry or urinalysis
  • Clinically significant abnormal physical examination, vital signs or 12 lead electrocardiogram (ECG)
  • Use of certain prescription or nonprescription medication, and consumption of products that may interfere with the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01487564

Taipei, Taiwan
Sponsors and Collaborators
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Development, L.L.C. Clinical Trial Janssen Research & Development, LLC
  More Information

Responsible Party: Janssen Research & Development, LLC Identifier: NCT01487564     History of Changes
Other Study ID Numbers: CR017701
42801PAI1011 ( Other Identifier: Janssen Research & Development, LLC )
Study First Received: December 5, 2011
Last Updated: March 1, 2013

Keywords provided by Janssen Research & Development, LLC:
Healthy volunteers
OROS Hydromorphone
UGT2B7 Gene

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 21, 2017